The aberrant expression of JMJD6 is involved in the etiology and progression of a spectrum of malignancies, such as melanoma,17 prostate18 and breast cancer.19 In the context of lung cancer, JMJD6 is postulated to act as an oncogene, facilitating epithelial-mesenchymal transition (EMT), a process closely linked to the acquisition of stem-like properties, yet its specific contribution to the modulation of tumor response to radiation therapy warrants further investigation.20 Here, JMJD6 is linked to breast carcinoma.